{
    "nctId": "NCT05525481",
    "briefTitle": "Tamoxifen Prediction Study in Patients With ER+ Breast Cancer",
    "officialTitle": "Predicting an Accurate Tamoxifen Dose: a Feasibility Study in Patients With Hormone Sensitive Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "ER+ Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Primary endpoint",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age \u2265 18 years;\n2. WHO Performance Status \u2264 1 (see Appendix A);\n3. Patients with primary breast cancer, with a prescription for adjuvant tamoxifen treatment;\n4. Willing to abstain from strong and moderate CYP3A4 or CYP2D6 inhibitors or inducers, according to: CYTOCHROME P450 DRUG INTERACTION TABLE - Drug Interactions (iu.edu);\n5. Able and willing to sign the Informed Consent Form;\n6. Able and willing to undergo blood sampling for PK analysis.\n\nExclusion Criteria:\n\n1. Patients with known alcoholism, drug addiction and/or psychiatric or physiological condition which in the opinion of the investigator would impair treatment compliance;\n2. \\> 2 weeks of tamoxifen treatment before inclusion;\n3. Patients who's endoxifen levels have been used for therapeutic drug monitoring in the past.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}